Takeda Pharmaceutical Co., Ltd. (TAK)
18.32
+0.08
(+0.44%)
USD |
NYSE |
Aug 25, 15:26
Takeda Pharmaceutical Enterprise Value : 85.21B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 85.21B |
| August 21, 2026 | 85.02B |
| August 20, 2026 | 84.87B |
| August 19, 2026 | 85.53B |
| August 18, 2026 | 84.61B |
| August 17, 2026 | 82.50B |
| August 14, 2026 | 83.29B |
| August 13, 2026 | 82.53B |
| August 12, 2026 | 82.59B |
| August 11, 2026 | 82.81B |
| August 10, 2026 | 83.03B |
| August 07, 2026 | 82.72B |
| August 06, 2026 | 81.36B |
| August 05, 2026 | 80.41B |
| August 04, 2026 | 79.90B |
| August 03, 2026 | 80.76B |
| July 31, 2026 | 81.58B |
| July 30, 2026 | 82.09B |
| July 29, 2026 | 83.67B |
| July 28, 2026 | 82.94B |
| July 27, 2026 | 82.69B |
| July 24, 2026 | 82.05B |
| July 23, 2026 | 80.73B |
| July 22, 2026 | 80.88B |
| July 21, 2026 | 82.02B |
| Date | Value |
|---|---|
| July 20, 2026 | 81.45B |
| July 17, 2026 | 81.77B |
| July 16, 2026 | 80.44B |
| July 15, 2026 | 79.56B |
| July 14, 2026 | 79.37B |
| July 13, 2026 | 79.68B |
| July 10, 2026 | 79.90B |
| July 09, 2026 | 80.06B |
| July 08, 2026 | 80.50B |
| July 07, 2026 | 81.17B |
| July 06, 2026 | 80.95B |
| July 02, 2026 | 80.57B |
| July 01, 2026 | 77.98B |
| June 30, 2026 | 78.23B |
| June 29, 2026 | 81.18B |
| June 26, 2026 | 80.96B |
| June 25, 2026 | 80.14B |
| June 24, 2026 | 80.36B |
| June 23, 2026 | 80.74B |
| June 22, 2026 | 79.57B |
| June 18, 2026 | 80.08B |
| June 17, 2026 | 79.41B |
| June 16, 2026 | 80.17B |
| June 15, 2026 | 80.52B |
| June 12, 2026 | 80.96B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Daiichi Sankyo Co., Ltd. | 31.92B |
| Ono Pharmaceutical Co., Ltd. | 6.571B |
| Astellas Pharma, Inc. | 29.10B |
| Sanofi | 120.17B |
| Eisai Co., Ltd. | 8.479B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 710.72M |
| Revenue (Quarterly) | 7.655B |
| Total Expenses (Quarterly) | 6.945B |
| EPS Diluted (Quarterly) | 0.2213 |
| Gross Profit Margin (Quarterly) | 57.57% |
| Profit Margin (Quarterly) | 9.28% |
| Earnings Yield | -1.84% |
| Operating Earnings Yield | 7.84% |
| Normalized Earnings Yield | -0.9793 |